Intercept Pharmaceuticals, Inc. (ICPT)

Intercept Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep 30, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Cash & Equivalents	102.74	50.52	84.71	58.15	70.06	43.25
Short-Term Investments	219.98	435.05	334.98	411.52	582.57	392.91
Cash & Short-Term Investments	322.71	485.57	419.69	469.67	652.62	436.16
Cash Growth	-34.25%	15.70%	-10.64%	-28.03%	49.63%	5.12%
Accounts Receivable	32.48	26.86	28.34	41.55	38.04	25.69
Other Receivables	1.1	2.4	1.3	2.5	-	-
Receivables	33.58	29.26	29.64	44.05	38.04	25.69
Prepaid Expenses	26.23	19.96	21.48	24.52	25.92	20.57
Restricted Cash	0.92	5.34	8.12	7.5	4.73	-
Other Current Assets	-	-	29.1	-	-	-
Total Current Assets	383.45	540.13	508.02	545.74	721.32	482.43
Property, Plant & Equipment	0.82	0.99	3.28	18.65	18.45	10.41
Other Long-Term Assets	8.9	12.6	15.72	16.1	15.12	16.33
Total Assets	393.16	553.71	527.02	580.49	754.89	509.17
Accounts Payable	10.27	14.23	17.6	24.59	18.98	11.77
Accrued Expenses	76.49	101.6	92.21	135.79	130.54	94.16
Current Portion of Long-Term Debt	-	109.57	-	-	-	-
Current Portion of Leases	-	-	-	7.25	6.46	-
Current Income Taxes Payable	2.87	3.14	-	-	-	-
Current Unearned Revenue	-	-	-	-	-	1.62
Other Current Liabilities	1.22	1.53	58.36	11.45	6.04	6.66
Total Current Liabilities	90.85	230.08	168.16	179.08	162.01	114.21
Long-Term Debt	223.86	223.1	539.78	560.58	532.08	371.25
Long-Term Leases	-	-	-	7.68	9.22	-
Long-Term Unearned Revenue	-	-	-	-	-	0.81
Other Long-Term Liabilities	6.62	7.45	3.04	-	0.03	3.77
Total Liabilities	321.32	460.63	710.99	747.34	703.33	490.04
Common Stock	0.04	0.04	0.03	0.03	0.03	0.03
Additional Paid-In Capital	2,257	2,238	2,309	2,234	2,176	1,800
Retained Earnings	-2,178	-2,137	-2,490	-2,398	-2,123	-1,779
Comprehensive Income & Other	-7.2	-8.26	-2.87	-2.48	-1.14	-2.26
Shareholders' Equity	71.85	93.08	-183.96	-166.85	51.56	19.13
Total Liabilities & Equity	393.16	553.71	527.02	580.49	754.89	509.17
Total Debt	223.86	332.67	539.78	575.51	547.76	371.25
Net Cash (Debt)	98.86	152.89	-120.09	-105.85	104.87	64.91
Net Cash Growth	-34.64%	-	-	-	61.56%	9.57%
Net Cash Per Share	2.37	4.52	-3.77	-3.21	3.31	2.28
Filing Date Shares Outstanding	41.83	41.67	29.69	33.02	32.85	29.69
Total Common Shares Outstanding	41.81	41.52	29.57	33.02	32.85	29.69
Working Capital	292.6	310.05	339.86	366.67	559.31	368.22
Book Value Per Share	1.72	2.24	-6.22	-5.05	1.57	0.64
Tangible Book Value	71.85	93.08	-183.96	-166.85	51.56	19.13
Tangible Book Value Per Share	1.72	2.24	-6.22	-5.05	1.57	0.64
Machinery	1.76	4.39	8.52	9.97	8.42	7.89
Leasehold Improvements	0.4	0.4	12.88	13.24	10.49	14.46

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q